EDWARD G. LUFKIN, M.D.; PAI CHIH KAO, Ph.D.; HUNTER HEATH III, M.D.
The determination of serum immunoreactive parathyroid hormone (iPTH) levels remains the most useful laboratory study in the differential diagnosis of hypercalcemia. The iPTH assay has been particularly valuable in distinguishing the two commonest hypercalcemic disorders, primary hyperparathyroidism and malignancy, which together account for more than 80% of cases of persistent hypercalcemia (1-3). The importance of distinguishing these two disorders lies in the great differences in their treatment and prognosis.
There are differences in predictive value among commercially available iPTH assays, and some confusion persists concerning the terms used to describe these assays. When Raisz and coworkers (4) submitted aliquots of
LUFKIN EG, KAO PC, HEATH H. Parathyroid Hormone Radioimmunoassays in the Differential Diagnosis of Hypercalcemia Due to Primary Hyperparathyroidism or Malignancy. Ann Intern Med. ;106:559–560. doi: 10.7326/0003-4819-106-4-559
Download citation file:
Published: Ann Intern Med. 1987;106(4):559-560.
Endocrine and Metabolism, Fluid and Electrolyte Disorders, Nephrology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use